Actions Panel

Foundations of Cancer Therapeutics: Commercialization

Foundations of Cancer Therapeutics: Commercialization

By Gulf Coast Consortia

Date and time

August 15, 2022 · 8am - August 19, 2022 · 1pm PDT

Location

Online

About this event

The GCC Innovative Drug Discovery and Development (IDDD) Consortium invites you to register to audit this short “crash” course that will cover various aspects of therapeutics commercialization career opportunities within this space. Though cancer will be highlighted, the various aspects of therapeutics commercialization and careers will be largely disease-agnostic, so all are welcome. Topics to be covered include 1) understanding disease, need, target population, market, and competitive landscape; 2) end game development goals and target produce profile; 3) strategies for when to file invention disclosures and patents and when to license; 4) commercialization strategies; 5) Funding; 6) preclinical/IND-enabling studies; 7) clinical trials; 8) NDA and post approval; and 9) the final day highlighting the Houston therapeutics landscape and small biotech companies. Career panel discussions will take place in the afternoon of each day. Confirmed speakers include: Dina Aziz, MDA; Jason Bock, CTMC, MDA; Rima Chakrabarti, KDT Ventures; Diana Chow, UH; Shahila Christie, Portal Ventures; Connie Coulomb, Biopharma Capital; Leah DiMascio, Hummingbird Bioscience; Enrique Gomez, TMC; Michael Heffernan, Fannin Innovation; Sarah Hein, TMC; Larry Hope, MDA; Phil Jones, MDA; Carla Kantara, Caris Life Sciences; Mansoor Khan, TAMU; Jeff Larson, Tvardi; Tom Luby, TMC; Christine Luk, Fannin Innovation; Lisa Mustachio, MDA; Edith Nagy, MDA; Sahar Paz, Own Your Voice; John Shultz, HMRI; Rick Silva, TAMU; Mick Soth, IACS; Sujatha Sridhar, UTH; Andrew Strong, Hogan Lovells; Suzanne Tomlinson, GCC; Wei Wan, TAMU; Stan Watowich, UTMB/Ridgeline Therapeutics; Huan Xie, TSU.

Organized by

The Gulf Coast Consortia (GCC) brings great minds together for the greater good—pushing the limits of what’s possible in the biosciences through collaboration with the greater scientific community.

The organization is a collaboration of basic and translational scientists, researchers, clinicians and students in the quantitative biomedical sciences who help advance the region’s scientific progress through participation in joint training and research programs, utilization of shared equipment and core facilities, and the exchange of scientific knowledge.

For more than a decade, the GCC has earned an unprecedented legacy for overcoming barriers between departments and institutions, increasing cooperation and collaborations, and training young scientists for future careers in the biomedical sciences.

The organization’s programs and core facilities are supported by the National Institutes of Health (NIH), the National Science Foundation (NSF), the Cancer Prevention and Research Institute of Texas (CPRIT),  John S. Dunn Foundation, and its member institutions.

Sales Ended